Equity Overview
Price & Market Data
Price: $0.193
Daily Change: -$0.0014 / 0.73%
Range: $0.183 - $0.197
Market Cap: $4,110,372
Volume: 138,910
Performance Metrics
1 Week: 8.01%
1 Month: -23.39%
3 Months: -32.08%
6 Months: -44.09%
1 Year: -81.80%
YTD: -47.77%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Products. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.